Abstract | INTRODUCTION: PATIENTS AND METHODS: RESULTS: A significant reduction of TC and LDL-C blood levels by 25% and 34% respectively, was observed during the first month of treatment with ezetimibe (p<0.001). This reduction was maintained for the whole period of ezetimibe administration. Renal function remained stable over the follow-up period, while no changes of the blood levels of immunosuppressive drugs were observed. Liver enzymes, LDH and CPK remained normal in all patients except for one diabetic patient who developed rhabdomyolysis. Apart from gastrointestinal symptoms in 2 patients, no other side effects were observed. CONCLUSION: Combination of ezetimibe with statins represents an effective and safe regimen for treatment of persistent hyperlipidemia in renal allograft recipients.
|
Authors | E Savvidaki, M Koukoulaki, A Benou, M Roumeliotou, C Fourtounas, P Kalliakmani, E Papachristou, J G Vlachojannis, D Goumenos |
Journal | Clinical nephrology
(Clin Nephrol)
Vol. 75
Issue 2
Pg. 107-12
(Feb 2011)
ISSN: 0301-0430 [Print] Germany |
PMID | 21255539
(Publication Type: Journal Article)
|
Chemical References |
- Anticholesteremic Agents
- Azetidines
- Biomarkers
- Cholesterol, HDL
- Cholesterol, LDL
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Immunosuppressive Agents
- Cholesterol
- Ezetimibe
|
Topics |
- Adult
- Anticholesteremic Agents
(adverse effects, therapeutic use)
- Azetidines
(adverse effects, therapeutic use)
- Biomarkers
(blood)
- Cholesterol
(blood)
- Cholesterol, HDL
(blood)
- Cholesterol, LDL
(blood)
- Drug Resistance
- Drug Therapy, Combination
- Ezetimibe
- Female
- Greece
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(adverse effects, therapeutic use)
- Hyperlipidemias
(blood, drug therapy, etiology)
- Immunosuppressive Agents
(blood, therapeutic use)
- Kidney Transplantation
(adverse effects)
- Male
- Middle Aged
- Retrospective Studies
- Time Factors
- Transplantation, Homologous
- Treatment Outcome
|